Kreutzer-Limmer patent family covered under the new license agreement.



Alnylam Pharmaceuticals granted Bio-Rad a nonexclusive license to provide RNAi research products under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers siRNAs and their use to mediate RNAi in mammalian cells.


“Execution of this license agreement with Bio-Rad continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi,” notes Roland Kreutzer, Ph.D., managing director of Alnylam Europe.


“This agreement brings the number of licenses that Alnylam has granted to more than 20, including 13 with research product suppliers. In fact, we believe that over 75 percent of industrial sales of siRNAs for research purposes are currently being made under access to Alnylam’s intellectual property.”








This site uses Akismet to reduce spam. Learn how your comment data is processed.